Merck (MRK) announces late-breaking data from Phase 3 trials, evaluating oravirine/islatravir (DOR/ISL), an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1
Importance
Level 1
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES